Orphan medicine will usher in a period of rapid development in China

[market analysis of chinapharma.com] "orphan medicine" is also known as rare medicine It is reported that only 1% of the 7000 kinds of rare diseases that have been found have effective treatment drugs for the cause of the disease, but the price is expensive and most patients can't bear it It is reported that the global multinational drug companies began to lay out more drugs for rare diseases, and the attention of drug companies in the development of drugs for rare diseases is no less than that of tumor and immune drugs For example, in the United States, orphan drugs are the cradle of "heavy bombs", and some are even the pillars of pharmaceutical giants In recent years, with the continuous introduction of supporting policies, more and more pharmaceutical enterprises find that this market is very huge Some regions in China have given corresponding medical subsidies for the treatment of rare diseases, such as Qingdao, Zhejiang and Shanghai In 2017, the national health insurance department also negotiated to include individual orphan drugs in the scope of medical insurance reimbursement It is understood that the 55 rare drugs included in the 2017 medical insurance drug catalog cover 17 kinds of rare diseases, including blood diseases, bone and cartilage diseases, congenital metabolic abnormalities, brain or nervous system diseases, immune diseases, skin diseases, digestive system diseases, endocrine diseases and other treatment fields Among them, there are 19 rare drugs in Category A, covering 11 rare diseases; 36 rare drugs in category B, covering 13 rare diseases The research and development of orphan drugs can not only make up for the shortage of drugs and meet the needs of patients, but also bring huge development opportunities for enterprises, which is worthy of great investment In recent years, China has also issued a series of policies and regulations to encourage the development of orphan drugs, such as special approval, special channels, priority review, and accelerated marketing of drugs for rare diseases According to the industry, on the one hand, there is a huge market with rapid growth, on the other hand, there is a new policy in China to encourage the development of orphan drugs Orphan drugs will usher in a period of rapid development in China in the future According to the newly released annual industry report "overview of drug market assessment in 2018 and outlook in 2024" released by evaluate, rare disease drugs are expected to remain one of the areas with rapid growth in the global pharmaceutical market in the next few years According to the report, global prescription drug sales are expected to increase to $1.2 trillion by 2024, while the market share in the field of rare diseases will reach an astonishing 20% Facing the huge market, some domestic pharmaceutical companies with sensitive sense of smell have begun to try to develop orphan drugs According to the industry, the research and development of orphan drugs can serve as a breakthrough in the development of China's innovative drugs, a way to achieve detour overtaking, and a shortcut for China's innovative drugs to go global With the introduction of new policies, many domestic enterprises will focus on orphan drug research and development, and international cooperation will increase But in the past, the development of orphan drugs in China was a blank field, and there was no experience to learn from The industry said that for those who are determined to take root in orphan drugs, looking abroad may be a better choice The current strategy is to research and develop new orphan drugs in the world, apply for approval in the United States for production and sales, and products approved abroad can be approved in China without clinical conditions Another strategy that can be adopted is to develop a new orphan drug in the world A considerable transfer fee can be obtained through the transfer of foreign rights and interests The Chinese rights and interests of the drug can be left in China and the drug can be developed in China The industry expects more domestic enterprises to invest in orphan drug R & D, and investment institutions can also pay attention to and invest in orphan drug R & D projects, create a good orphan drug R & D ecological environment, and develop affordable orphan drugs for the vast number of Chinese patients with rare diseases.